CN109963842A - 苯并咪唑类化合物激酶抑制剂及其制备方法和应用 - Google Patents

苯并咪唑类化合物激酶抑制剂及其制备方法和应用 Download PDF

Info

Publication number
CN109963842A
CN109963842A CN201780050147.3A CN201780050147A CN109963842A CN 109963842 A CN109963842 A CN 109963842A CN 201780050147 A CN201780050147 A CN 201780050147A CN 109963842 A CN109963842 A CN 109963842A
Authority
CN
China
Prior art keywords
base
alkyl
amino
fluoro
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780050147.3A
Other languages
English (en)
Other versions
CN109963842B (zh
Inventor
刘世强
周远峰
吴雪松
包如迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201710157847.4A external-priority patent/CN107793399A/zh
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority to CN202011082470.9A priority Critical patent/CN112225724B/zh
Priority to CN202011099789.2A priority patent/CN112250669B/zh
Publication of CN109963842A publication Critical patent/CN109963842A/zh
Application granted granted Critical
Publication of CN109963842B publication Critical patent/CN109963842B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

提供一种通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为苯并咪唑类化合物激酶抑制剂在制备预防和/或治疗癌症或肿瘤相关疾病特别是膀胱癌、卵巢癌、腹膜癌、胰腺癌、乳腺癌、子宫癌、子***、子宫内膜癌、***癌、雌性生殖道癌、睾丸癌、胃肠道间质瘤或***肿瘤等疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201780050147.3A 2016-09-07 2017-09-06 苯并咪唑类化合物激酶抑制剂及其制备方法和应用 Active CN109963842B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202011082470.9A CN112225724B (zh) 2016-09-07 2017-09-06 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
CN202011099789.2A CN112250669B (zh) 2016-09-07 2017-09-06 苯并咪唑类化合物激酶抑制剂及其制备方法和应用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2016108091544 2016-09-07
CN201610809154 2016-09-07
CN2017101578474 2017-03-16
CN201710157847.4A CN107793399A (zh) 2016-09-07 2017-03-16 Cdk4/6抑制剂及其制备方法和应用
CN201710338488 2017-05-15
CN2017103384882 2017-05-15
PCT/CN2017/100678 WO2018045956A1 (zh) 2016-09-07 2017-09-06 苯并咪唑类化合物激酶抑制剂及其制备方法和应用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202011099789.2A Division CN112250669B (zh) 2016-09-07 2017-09-06 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
CN202011082470.9A Division CN112225724B (zh) 2016-09-07 2017-09-06 苯并咪唑类化合物激酶抑制剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN109963842A true CN109963842A (zh) 2019-07-02
CN109963842B CN109963842B (zh) 2020-11-03

Family

ID=61561722

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202011099789.2A Active CN112250669B (zh) 2016-09-07 2017-09-06 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
CN202011082470.9A Active CN112225724B (zh) 2016-09-07 2017-09-06 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
CN201780050147.3A Active CN109963842B (zh) 2016-09-07 2017-09-06 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
CN201780049731.7A Active CN109952295B (zh) 2016-09-07 2017-09-06 一种cdk4/6抑制剂及其制备方法和应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202011099789.2A Active CN112250669B (zh) 2016-09-07 2017-09-06 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
CN202011082470.9A Active CN112225724B (zh) 2016-09-07 2017-09-06 苯并咪唑类化合物激酶抑制剂及其制备方法和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780049731.7A Active CN109952295B (zh) 2016-09-07 2017-09-06 一种cdk4/6抑制剂及其制备方法和应用

Country Status (3)

Country Link
CN (4) CN112250669B (zh)
TW (1) TWI765908B (zh)
WO (2) WO2018045957A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574191A (zh) * 2019-09-29 2021-03-30 南京圣和药业股份有限公司 异噁唑杂环类化合物及其应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108794452B (zh) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
AU2018388404B2 (en) 2017-12-22 2023-11-02 HiberCell Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
CN110156754B (zh) * 2018-02-10 2023-10-03 杭州百诚医药科技股份有限公司 一种三取代嘧啶衍生物对蛋白激酶的抑制作用
EP3801529B1 (en) 2018-05-25 2023-10-11 OncoCube Therapeutics LLC Highly potent tacc3 inhibitor as a novel anticancer drug candidate
CA3107750A1 (en) * 2018-07-27 2020-01-30 California Institute Of Technology Cdk inhibitors and uses thereof
CN110790748B (zh) * 2018-08-02 2022-04-19 江苏豪森药业集团有限公司 细胞周期蛋白依赖性激酶抑制剂的对甲苯磺酸盐晶型及其制备方法和用途
CN111138413B (zh) * 2018-11-01 2022-11-04 江苏豪森药业集团有限公司 一种细胞周期蛋白依赖性激酶抑制剂的制备方法及其中间体
CN111606889B (zh) * 2019-02-25 2023-03-07 上海翰森生物医药科技有限公司 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法
EP3966213A4 (en) * 2019-05-05 2023-04-19 Qilu Regor Therapeutics Inc. CDK INHIBITORS
CN110305125B (zh) * 2019-06-06 2021-09-03 山东新华制药股份有限公司 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用
TW202237585A (zh) 2020-11-27 2022-10-01 瑞士商瑞森製藥公司 Ｃｄｋ抑制劑
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CA3216541A1 (en) * 2021-04-12 2022-10-20 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer
CN113135898B (zh) * 2021-04-15 2022-02-11 中国药科大学 一种抗癌喹喔啉嘧啶胺杂环化合物及其制备方法和应用
CN115246822A (zh) * 2021-04-27 2022-10-28 中国科学院上海药物研究所 嘧啶类化合物及其制备方法和用途
CN113264920B (zh) * 2021-05-10 2022-09-02 中国药科大学 一种嘧啶苯并六元环母核的cdk6抑制剂及其制备方法和应用
CN113248500B (zh) * 2021-06-10 2021-10-19 中国药科大学 氮杂吲哚嘧啶胺杂环化合物及其制备方法和应用
WO2024051702A1 (zh) * 2022-09-05 2024-03-14 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160340A1 (en) * 2008-12-22 2010-06-24 Coates David A Protein kinase inhibitors
CN105153119A (zh) * 2015-09-11 2015-12-16 广州科擎新药开发有限公司 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用
CN105294683A (zh) * 2014-07-26 2016-02-03 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
CN104529904B (zh) * 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 玻玛西尼的制备方法
CN106467517B (zh) * 2015-08-14 2019-09-06 正大天晴药业集团股份有限公司 氘修饰的Abemaciclib衍生物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160340A1 (en) * 2008-12-22 2010-06-24 Coates David A Protein kinase inhibitors
CN105294683A (zh) * 2014-07-26 2016-02-03 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
CN105294655A (zh) * 2014-07-26 2016-02-03 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
CN105153119A (zh) * 2015-09-11 2015-12-16 广州科擎新药开发有限公司 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574191A (zh) * 2019-09-29 2021-03-30 南京圣和药业股份有限公司 异噁唑杂环类化合物及其应用
CN112574191B (zh) * 2019-09-29 2024-01-23 南京圣和药业股份有限公司 异噁唑杂环类化合物及其应用

Also Published As

Publication number Publication date
CN112250669B (zh) 2022-02-25
TW201811771A (zh) 2018-04-01
CN109952295B (zh) 2021-04-06
CN109963842B (zh) 2020-11-03
WO2018045957A1 (zh) 2018-03-15
CN112250669A (zh) 2021-01-22
WO2018045956A1 (zh) 2018-03-15
CN112225724A (zh) 2021-01-15
TWI765908B (zh) 2022-06-01
CN109952295A (zh) 2019-06-28
CN112225724B (zh) 2022-04-29

Similar Documents

Publication Publication Date Title
CN109963842A (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
KR102387316B1 (ko) Mdm2 단백질 분해제
CN104011052B (zh) 化合物
ES2742409T3 (es) Inhibidores de quinasa de pirazolilquinoxalina
EP3533796B1 (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
CN103038233B (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法
JP6165977B2 (ja) ヘテロアリールピリドン及びアザ−ピリドンアミド化合物
CN114502158A (zh) Irak降解剂及其用途
JP6507234B2 (ja) ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
BR112017027241B1 (pt) Inibidores de hpk1 e composição farmacêutica
JP6522646B2 (ja) ＲＯＳ１阻害剤としての置換４，５，６，７−テトラヒドロ−ピラゾロ［１，５−α］ピラジン誘導体および５，６，７，８−テトラヒドロ−４Ｈ−ピラゾロ［１，５−α］［１，４］ジアゼピン誘導体
JP2017536369A (ja) Ｉｒａｋインヒビターとしてのヘテロアリール化合物及びその使用
WO2014040555A1 (zh) 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
JP6557331B2 (ja) Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用
CN103214484A (zh) 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
TW201838981A (zh) 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
CA3001452A1 (en) Compounds for treatment of cancer and epigenetics
CN114828959B (zh) 3-(5-甲氧基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
JP2021536436A (ja) キノリン誘導体から調製される新規な阻害剤
CN107793399A (zh) Cdk4/6抑制剂及其制备方法和应用
WO2022111526A1 (zh) 一种苯环衍生物及其组合物和药学上的应用
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
WO2020192750A1 (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
CN108299420B (zh) 作为选择性***受体下调剂的五环类化合物及其应用
WO2020169058A1 (zh) Pd-l1拮抗剂化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003421

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant